Jonathan Zalevsky is Chief R&D Officer at NEKTAR THERAPEUTICS (NKTR). They have made 31 open-market trades across 1 company since 2019, most recently 2026-08-18.
CIK 0001789857
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 31 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NKTR | 9,570 | $368K |
Shares reported on the most recent Form 4, priced at the 2026-08-20 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NKTR | SELL | 2026-08-18 | 2026-08-20 | $71.98 | $13K | -4.8% | -11.5% | — |
| NKTR | SELL · 10b5-1 | 2026-06-30 | 2026-07-02 | $70.00 | $398K | -3.3% | -0.1% | -14.3% |
| NKTR | SELL · 10b5-1 | 2026-06-15 | 2026-06-17 | $60.71 | $336K | +13.6% | +11.0% | +8.5% |
| NKTR | SELL | 2026-05-19 | 2026-05-21 | $65.51 | $13K | -12.1% | -2.6% | +12.8% |
| NKTR | SELL | 2026-02-18 | 2026-02-20 | $73.00 | $13K | -3.3% | +1.0% | -6.7% |
| NKTR | SELL · 10b5-1 | 2026-01-20 | 2026-01-22 | $35.67 | $138K | +2.7% | +94.7% | +146.5% |
| NKTR | SELL | 2025-11-25 | 2025-11-25 | $54.28 | $126K | -9.2% | -29.5% | +16.7% |
| NKTR | SELL · 10b5-1 | 2025-09-04 | 2025-09-08 | $33.52 | $58K | +32.8% | +27.8% | +29.4% |
| NKTR | SELL · 10b5-1 | 2025-09-02 | 2025-09-04 | $30.10 | $15K | +38.7% | +66.7% | +58.9% |
| NKTR | SELL | 2025-08-19 | 2025-08-21 | $26.59 | $19K | +1.8% | +110.0% | +115.2% |
| NKTR | SELL | 2025-05-19 | 2025-05-21 | $0.67 | $7K | +20.9% | -8.5% | +187.3% |
| NKTR | SELL | 2025-02-19 | 2025-02-21 | $1.01 | $10K | -4.9% | -4.7% | -26.9% |
| NKTR | SELL | 2024-12-19 | 2024-12-20 | $0.94 | $48K | +18.5% | -2.6% | -5.9% |
| NKTR | SELL | 2024-11-19 | 2024-11-20 | $1.01 | $8K | +7.0% | -7.2% | +6.0% |
| NKTR | SELL | 2024-08-19 | 2024-08-20 | $1.28 | $9K | -2.3% | -3.1% | -21.4% |
| NKTR | SELL | 2024-05-17 | 2024-05-20 | $1.75 | $13K | -27.0% | -37.4% | -23.6% |
| NKTR | SELL | 2024-02-20 | 2024-02-22 | $0.68 | $6K | +36.1% | +36.7% | +169.4% |
| NKTR | SELL | 2023-11-17 | 2023-11-20 | $0.49 | $5K | +2.9% | -7.0% | +30.1% |
| NKTR | SELL | 2023-08-16 | 2023-08-17 | $0.78 | $8K | -13.7% | -4.8% | -27.1% |
| NKTR | SELL | 2023-05-16 | 2023-05-17 | $0.72 | $7K | -12.3% | -19.4% | +14.0% |
| NKTR | SELL | 2023-02-16 | 2023-02-17 | $3.00 | $31K | -49.2% | -69.3% | -77.9% |
| NKTR | SELL | 2022-11-16 | 2022-11-18 | $3.57 | $48K | -16.0% | -28.9% | -13.1% |
| NKTR | SELL | 2022-08-18 | 2022-08-19 | $4.65 | $686K | -13.2% | -21.8% | -24.4% |
| NKTR | SELL | 2022-08-16 | 2022-08-17 | $4.76 | $101K | -7.8% | -25.2% | -15.5% |
| NKTR | SELL | 2022-05-16 | 2022-05-17 | $3.95 | $171K | -7.6% | -15.4% | +28.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.